Business Wire Named as a Challenger in 2023 Gartner® Magic Quadrant™ for Enterprise Conversational AI Platforms

Share, a leading conversational AI platform, today announced it has been recognized as a Challenger by Gartner in their 2023 Magic Quadrant for Enterprise Conversational AI Platforms. For the second consecutive year, has been recognized in this Magic Quadrant by Gartner for its Ability to Execute and Completeness of Vision. We believe being recognized as a Challenger reinforces the company’s strength and leadership within the conversational AI space, as it continues to expand its technology and support a growing roster of clients across the globe.

The report states that “Gartner defines the enterprise conversational AI platform market as the market for software platforms used to build, orchestrate, and maintain multiple use cases of modalities of conversational automation.” As expectations for quality customer service continue to rise globally, has refined its technology, deploying industry-leading virtual agents that scale to meet the requirements of enterprise organizations.’s solution is powered by conversational AI, and the platform allows customers to scale up individually to thousands of industry-specific intents, enabling these businesses to effectively manage a very broad scope of customer queries in a matter of weeks in virtually any industry. With consistent 90% resolution rates, the solution facilitates immediate responses with accuracy, while its no-code conversation builder and AI trainer program allow customers to self-service their virtual agents and easily deploy service flows in response to customer feedback.

“Customer experience and digital transformation continue to be a priority, and I’m proud to say we have executed on this priority at Over the last year, we’ve set customers up for success with our easily adaptable and scalable technology, and have solidified ourselves as world leaders in delivering the best possible customer experience for clients,” said Jerry Haywood, CEO of “From my perspective, our placement in the 2023 Gartner Magic Quadrant is a testament to the work our team has done to perfect our solution and expand our existing offers based on new trends and technology.”

We believe this latest Magic Quadrant report encapsulates a strong previous year for, in which the company announced multiple customer wins and partnerships in the US and UK including Aspire Insurance, Metrobank, CallMiner, and Clarasys. The company also appointed Jerry Haywood as the new CEO, bringing 20 years of enterprise technology experience. With a conversational AI platform that delivers unlimited scalability as its central offering, is now leveraging its technology to tackle a new AI frontier: large language models (LLMs). combines the generative capabilities of LLMs like GPT-3, with company data to optimize their virtual agents for improved accuracy and brand alignment. As these models continue to develop, is working to ensure the technology can be properly integrated to offer the most advanced enterprise solution possible for both chat and voice.

"It’s an exciting time to be in the conversational AI space as the technology has taken another leap forward with the recent advancement of powerful LLMs. We think Future Gartner Magic Quadrant reports in this category could very well be defined by how well providers respond to this trend. We’re confident that we’re integrating the tech in a way that increases efficiency and performance, but most importantly is brand safe for our customers," said Lars Ropeid Selsås, Founder of “I'm excited to see the massive amount of improvement our team and solution made in just one year, and now we can set our sights on solidifying our position in the market even further." continues its upward global trajectory within the Enterprise Conversational AI market. The platform will focus on continuing to innovate and stay at the forefront of helping enterprise organizations to deliver exceptional customer experiences.

To learn more about how is empowering customers like DNB and Aspire Insurance using conversational AI, please visit:

Gartner Disclaimer:

GARTNER is a registered trademark and service mark of Gartner Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Jon Burch
+44 208 819 3170

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release

RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict

IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release

IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating

Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release

Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla

Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release

Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m

Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™7.6.2023 17:00:00 EEST | Press release

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. This press release features multimedia. View the full release here: CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom